Welcome to our dedicated page for Salarius Pharmaceuticals SEC filings (Ticker: SLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) SEC filings page aggregates the company’s official submissions to the U.S. Securities and Exchange Commission, providing structured access to the regulatory record behind its transformation and financing activities. These documents include current reports on Form 8‑K, registration statements on Form S‑1, and proxy materials on Schedule 14A, among others.
For this issuer, Form 8‑K filings are particularly important. They detail key events such as the completion of the strategic merger with Decoy Therapeutics, the issuance of Series A and Series B Non‑Voting Convertible Preferred Stock, underwritten public offerings of common stock and warrants, reverse stock split implementation, Nasdaq listing compliance updates and notices related to minimum bid price and equity standards. One 8‑K filed in early 2026 describes a Nasdaq notice regarding non-compliance with the minimum bid price requirement and the company’s stated intention to appeal a delisting determination to a Nasdaq Hearings Panel.
Registration statements on Form S‑1 and their amendments outline the terms of public offerings, including the number of shares, pre-funded warrants, Series A and Series B warrants and representative warrants, as well as intended use of proceeds such as advancing research and development programs and addressing Decoy promissory notes. The DEF 14A definitive proxy statement provides insight into corporate governance, board elections, executive compensation proposals and the conduct of the 2025 Annual Meeting of Stockholders.
On Stock Titan, these filings are paired with AI-powered summaries that explain complex structures in accessible language, highlighting elements such as the preferred stock conversion mechanics tied to the Decoy merger, conditions for Nasdaq initial listing standards, and the implications of reverse stock splits and listing notices. Users can quickly locate quarterly and annual reports when available, review historical and current 8‑Ks, and examine equity and warrant terms without reading every page of the original documents.
Because insider transaction information for SLRX, when filed on Form 4 or related ownership forms, also appears in the SEC’s EDGAR system, this page serves as a starting point for tracking changes in beneficial ownership alongside the broader corporate actions disclosed by Salarius and its successor branding as Decoy Therapeutics.
Salarius Pharmaceuticals (SLRX) reported an insider stock purchase by its Executive VP Finance and CFO, Mark J. Rosenblum. On 11/20/2025, he bought 20,000 shares of Salarius common stock at a price of $0.80 per share in an open-market transaction. After this purchase, he beneficially owns 20,177 shares of common stock, which includes 20 shares of unvested restricted stock granted on January 3, 2023. The reported post-transaction share amount reflects prior reverse stock splits that were effective on June 16, 2024 and August 17, 2025.
Salarius Pharmaceuticals, Inc. (SLRX) entered into new employment agreements with three senior leaders on November 18, 2025. Frederick E. Pierce will serve as Chief Executive Officer, Dr. Barbara Hibner as Chief Scientific Officer, and Peter Marschel as Chief Business Officer.
Each executive will receive an annual base salary of $225,000 and is eligible for a target annual bonus equal to 35% of base salary, based on performance objectives set by the board’s compensation committee. They will also be able to participate in the company’s standard executive benefit plans, such as medical, dental, life and disability coverage, subject to potential future changes by the company.
If an executive is terminated without cause or resigns for good reason, the agreement provides severance equal to $225,000 plus nine months of COBRA premium reimbursements at active employee rates, conditioned on signing a release of claims. Termination for cause, death, disability, or resignation without good reason limits payments to accrued salary, unused vacation, applicable benefits and reimbursable expenses.
Salarius Pharmaceuticals, Inc. clarifies that its common stock remains listed and trading on the Nasdaq Capital Market under the ticker “SLRX”. The company became aware that certain financial data platforms, including Yahoo Finance and CapIQ, incorrectly reported that it had been delisted effective November 13, 2025, and has contacted them to correct this error.
The company notes that it regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price rule, as of a letter dated September 4, 2025, and later regained compliance with Nasdaq Listing Rule 5550(b)(1), the equity standard, as of an October 10, 2025 letter. Salarius also highlights that, following completion of its strategic merger with Decoy Therapeutics, Inc. on November 13, 2025, it continues to meet the continued listing requirements and has not received any non-compliance notice from Nasdaq.
Salarius Pharmaceuticals (SLRX) filed its Q3 2025 10‑Q, reporting a net loss of $873,467 for the quarter and $3,540,825 for the nine months ended September 30, 2025. Operating expenses fell year over year, with research and development at $61,826 and general and administrative at $833,304 in Q3. Cash and cash equivalents were $4,809,680, and stockholders’ equity was $4,248,065.
The company disclosed substantial doubt about its ability to continue as a going concern, citing its lack of product revenue and recurring losses. Cash used in operations was $3,690,700 for the nine months, offset by $6,265,852 provided by financing activities.
Subsequent events: on November 12, 2025, Salarius closed its merger with Decoy Therapeutics and issued Series A and Series B non‑voting convertible preferred stock, together representing 4,814,106 underlying common shares subject to stockholder and Nasdaq approvals and beneficial ownership limits. The company also completed a public offering with approximately $6.3 million in net proceeds and reported 5,862,178 common shares outstanding as of November 12, 2025.
Salarius Pharmaceuticals (SLRX) completed a public offering and closed its merger with Decoy Therapeutics. The offering, led by Ladenburg Thalmann, raised approximately $6.3 million in net proceeds. It included 2,514,335 common shares, pre-funded warrants for up to 2,152,331 shares, and Series A and Series B warrants each exercisable for up to 4,666,666 shares. The underwriter exercised its option for 665,729 additional shares plus 699,999 Series A and 699,999 Series B warrants. Pricing was $1.50 per common share with accompanying warrants and $1.4999 per pre-funded warrant with accompanying warrants.
Proceeds will advance R&D, repay certain Decoy promissory notes, and fund general corporate needs. Series A and B warrants are immediately exercisable at $1.50; Series A expires in five years and Series B in one year. Representative warrants cover 266,620 shares at $2.325. After closing, 4,231,846 common shares were outstanding, with pre-funded warrants for 2,152,331 additional shares. The Decoy merger closed, and anti-dilution terms reset the Series A and B preferred conversion ratio to 2,800‑to‑1, with conversion contingent on stockholder and Nasdaq approvals and subject to 4.99% (or 9.99%) beneficial ownership limits.
Salarius Pharmaceuticals (SLRX) launched a primary offering of 2,514,335 shares of common stock at $1.50 per share, together with Series A and Series B warrants to purchase up to 4,666,666 shares each, pre-funded warrants for up to 2,152,331 shares, representative warrants for up to 233,333 shares, and up to 11,718,996 underlying shares issuable upon warrant exercise.
The deal is priced at a combined $1.50 per share and accompanying common warrants, for gross proceeds of $6,999,783.77 and proceeds before expenses of $6,369,803.23. Underwriters have a 45‑day option to purchase up to 699,999 additional shares and/or common warrants; representative warrants equal to 5% of shares/pre-funded warrants sold carry a $2.325 exercise price.
Concurrently, Salarius and Decoy plan to close step one of their merger, with Preferred Stock structured to convert only after Nasdaq initial listing approval and stockholder approval. Based on the $1.50 offering price and anti-dilution terms (Initial Issuance Price $10.50; Floor Price $3.75), Decoy holders are expected to own approximately 82.1% and legacy Salarius holders about 17.9% before this offering’s dilution, with 4,814,106 shares underlying the Preferred Stock.
Salarius Pharmaceuticals, Inc. filed its definitive proxy for the 2025 Annual Meeting, to be held virtually at 10:00 AM CST on December 19, 2025 at www.virtualshareholdermeeting.com/SLRX2025.
Stockholders will vote on: (1) electing two Class I directors to serve until the 2028 meeting, (2) a non‑binding advisory vote on executive compensation, and (3) ratification of Ernst & Young LLP as independent auditor for fiscal 2025. The Board recommends voting FOR all nominees and FOR Proposals 2 and 3.
The record date is October 24, 2025, with 1,051,782 shares outstanding and entitled to vote. Internet and telephone proxies are accepted until 11:59 PM ET on December 18, 2025. A quorum requires at least 34% of outstanding shares. Broker non‑votes apply only to the routine auditor ratification proposal.
All share figures in the proxy reflect the Company’s 1‑for‑15 reverse stock split effected on August 15, 2025. The Board comprises seven directors across three staggered classes, with independence determined under Nasdaq rules.
Salarius Pharmaceuticals (SLRX) filed Amendment No. 7 to its S-1 for a primary offering of 1,960,784 shares of common stock (or pre-funded warrants in lieu of shares) together with Series A warrants for up to 1,960,784 shares and Series B warrants for up to 1,960,784 shares. The filing also covers representative warrants for up to 98,039 shares and up to 5,980,391 shares issuable upon exercise of the pre-funded and common warrants. The assumed combined public offering price is $4.08 per share and accompanying warrants.
The common warrants are exercisable upon issuance; Series A expire in five years and Series B in one year. Pre-funded warrants carry a $0.0001 exercise price and are offered to maintain 4.99% (or 9.99%) ownership limits. Underwriters have a 45‑day option to purchase up to 294,118 additional shares and/or warrants.
The offering is tied to Salarius’ planned merger with Decoy Therapeutics. Based on an assumed price of $4.08 and the merger exchange mechanics, legacy Salarius holders would own ~14.8% and Decoy holders ~85.2% of the company before this offering’s dilution. Preferred stock issued at closing includes price protection down to a $3.75 floor, with an initial reference price of $10.50. As of October 14, 2025, Salarius estimated $4.3 million in cash and cash equivalents, and it has regained Nasdaq compliance with bid price and equity standards.
Salarius Pharmaceuticals (SLRX) approved a transaction bonus for its Acting CEO, EVP & CFO, Mark J. Rosenblum. The Board authorized a $225,000 cash bonus, payable following the closing of the transactions contemplated by the Merger Agreement with Decoy Therapeutics.
Payment requires Mr. Rosenblum’s continued employment through the Closing Date and will be paid at or before the next payroll date after closing.
Salarius Pharmaceuticals (SLRX) announced it has regained compliance with Nasdaq’s minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), as confirmed by a Nasdaq Hearings Panel on October 10, 2025.
Nasdaq placed the company under a one-year Mandatory Panel Monitor starting October 10, 2025. If Salarius falls out of compliance with the equity standard during this monitoring period, Nasdaq staff will issue a delisting determination without allowing a compliance plan or cure period; Salarius would retain the right to request a hearing.
On October 13, 2025, the company issued a press release reiterating its compliance status.